. 2006 Apr;172(4):2123–2138. doi: 10.1534/genetics.105.048231

TABLE 2.

Genetic and phenotypic properties of new ADR mutants

		Allele
Complementation group	Gene	MATa	MATα	Additional phenotypes
I	ADR11	33,^a 38, 48,^a ^b 109, 114,^a 37^a ^b	1, 30, 32, 62	Elevated ADH2 Expression at 25°C
II	ADR12	17^a	5, 9, 59, 89^a ^b	Abn
III	ADR13	70, 112	19, 35, 85	Spo⁻
IV	ADR14	103, 119^a	6, 10	Abn
V	ADR15	3,^b 15	52	Spo⁻
VI	ADR16	3,^b 63,^a 101^a	25
VII	ADR17	110	20, 66	Spo⁻ Inv^C
VIII	ADR18	53, 117,^a 141	49	ts, hs, Abn Inv^C
IX	ADR19	37,^a ^b 59, 127, 128	44	ts, hs, Inv^C
X	ADR20	16, 43	97, 102
XI	ADR21	44, 48,^a ^b 105, 115^a ^b	79	ts
XII	ADR22	115^a ^b	89^a ^b	ts

Additional mutants that did not fall into any of the complementation groups are not shown and were not studied further except for two that failed to complement known genes. They are mutant 13a, a temperature-sensitive mutant that failed to complement mutations in ADR7, and mutant 78a, which failed to complement mutations in ADR8.

Spo⁻, sporulation deficiency in heterozygous diploids; Abn, abnormal cell morphology; Inv^C, constitutive invertase activity; ts, temperature sensitive; hs, heat-shock sensitive.

Phenotype is due to a single gene.

Shows nonallelic noncomplementation. That is, it complements mutants in more than one complementation group. For example, VMY89α fails to complement mutants in both complementation group II and complementation group XII. In the case of VMY89α and VMY115a, the true complementation group is XII; for VMY48a, the true complementation group is I; and for VMY37a, the true complementation group is IX, as described in the text. The true complementation group for VMY3a was not determined.